BC Extra | Oct 29, 2019
Company News

Oct. 28 Company Quick Takes: MOR106 dropped in atopic dermatitis; plus Blueprint, Merus, Gilead-Glympse, Heron and GSK

Galapagos, MorphoSys, Novartis discontinue atopic dermatitis program  With an interim analysis indicating futility of the Phase II IGUANA trial, MorphoSys AG (Xetra:MOR; NASDAQ:MOR), Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and Novartis AG (NYSE:NVS; SIX:NOVN) terminated development of...
BioCentury | Jun 28, 2019
Product Development

Why tissue-agnostic drug development needs NGS to go mainstream

Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable...
BC Innovations | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Jun 16, 2018
Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
BC Innovations | May 24, 2018
Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
BC Week In Review | Jun 6, 2016
Clinical News

Patritumab: Phase III discontinued

Daiichi discontinued the double-blind, placebo-controlled, international Phase III HER3-Lung trial of IV patritumab after an IDMC concluded the study’s first part assessing PFS did not meet the predefined efficacy criteria. The IDMC did not identify...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
BC Week In Review | Jan 4, 2016
Clinical News

Seribantumab: Phase II amended

Merrimack amended an open-label, international Phase II trial of IV MM-121 to change the primary endpoint to OS from PFS to support potential registration. The trial is comparing MM-121 plus investigator’s choice of docetaxel or...
BC Innovations | Sep 10, 2015
Emerging Company Profile

Epitope as prologue

Most antibody platforms target specific antigens, but offer little control over the exact binding location on the target or how the antibody affects activity. Hummingbird Bioscience Pte. Ltd. has developed a system for pinpointing the...
Items per page:
1 - 10 of 42